All In Biotech

Drug Trial Radar · NCT07699328

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

A Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of VRN110755 in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

315

Planned (sponsor's estimate)

Start

Mar 26, 2024

Primary completion

Jan 1, 2029

Study completion Oct 1, 2029

Sponsor

Lead sponsor
Voronoi, IncIndustry
Sponsor type
Industry
First posted
Jul 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of VRN110755, a highly selective oral epidermal growth factor receptor (EGFR) inhibitor, in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The study includes a Phase 1a dose-escalation portion, a Phase 1b dose-expansion portion, and a Phase 2 evaluation. The study is designed to determine the maximum tolerated dose and recommended Phase 2 dose of VRN110755 and to evaluate preliminary and confirmatory antitumor activity in patients with EGFR-mutant NSCLC, including patients with acquired resistance following EGFR tyrosine kinase inhibitor therapy.

Conditions

  • EGFR-Mutant Non-Small Cell Lung Cancer

Interventions

  • VRN110755Drug

    VRN110755 is an investigational highly selective oral EGFR inhibitor supplied as capsules for oral administration. The drug is designed to target activating EGFR mutations and selected resistance mutations, including C797S, in patients with EGFR-mutant NSCLC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate of Maximum Tolerated Dose (MTD) of VRN110755Time frame: 28 days
  2. Number of participants with dose-limiting toxicities (DLTs) following treatment with VRN110755Time frame: 28 days
  3. Number of participants experiencing treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuationTime frame: From first dose until end of study (up to approximately 6 years)
  4. Number of participants with changes in vital signs from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
  5. Number of participants with changes in laboratory test results from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
  6. Number of participants with changes in physical examination findings from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
  7. Number of participants with changes in ophthalmologic examination findings from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
  8. Number of participants with changes in electrocardiogram (ECG) parameters from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)
  9. Number of participants with changes in Eastern Cooperative Oncology Group (ECOG) Performance Status from baseline following treatment with VRN110755Time frame: From baseline through End of Treatment (up to approximately 6 years)

Locations

29 sites in 10 countries. Site status is shown where the registry gives one.

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, Australia · Recruiting

  • Monash Medical Centre Clayton

    Clayton, Victoria, Australia · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • AP-HM Hôpital Nord

    Marseille, Bouches-du-Rhône, France · Recruiting

  • Centre Georges François Leclerc

    Dijon, Côte-d'Or, France · Recruiting

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Recruiting

  • Queen Mary Hospital

    Hong Kong, Hong Kong · Recruiting

  • Hospital Kuala Lumpur

    Kuala Lumpur, Malaysia · Recruiting

  • University Malaya Medical Centre

    Kuala Lumpur, Malaysia · Recruiting

  • Institut Kanser Negara

    Putrajaya, Malaysia · Recruiting

  • Hospital Umum Sarawak

    Kuching, Sarawak, Malaysia · Recruiting

  • National Cancer Centre Singapore

    Singapore, Singapore · Recruiting

  • Tan Tock Seng Hospital

    Singapore, Singapore · Recruiting

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • The Catholic University of Korea, St. Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, South Korea · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Regional Universitario de Málaga - Hospital Civil

    Málaga, Spain · Recruiting

  • ICO Badalona - Hospital Universitari Germans Trias i Pujol

    Badalona, Barcelona, Spain · Recruiting

  • ICO l'Hospitalet - Hospital Duran i Reynals

    L'Hospitalet de Llobregat, Barcelona, Spain · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Medical University Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • Phramongkutklao Hospital

    Thung Phaya Thai, Bangkok Metropolis, Thailand · Recruiting

  • Songklanagarind Hospital Prince of Songkla University

    Hat Yai, Changwat Songkhla, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.